Novo Nordisk A/S
Novo Nordisk A/S (NONOF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nonof · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Novo Nordisk A/S (NONOF) measures how much investors pay for each dollar of the company's trailing earnings. NONOF's current PE ratio of 9.91x is calculated by dividing its stock price of $41.25 by its TTM earnings per share of $27.45. −67.4% discount vs 5Y avg 30.4x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%26.9x
MedianQ3 · 75%121.2x
Max
At 9.91x, NONOF's current P/E is lower than in 0% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novo Nordisk A/SYou NONOF | $183.3B | 9.91x | -77.7% | $27.45 |
 AstraZeneca PLC AZNCF | $294.4B | 26.60x | -40.1% | $6.60 |
 CSL Limited CMXHF | $33.8B | 26.29x | -40.8% | $6.20 |
 CSL Limited CSLLY | $66.3B | 51.08x | +15.0% | $0.78 |
 EssilorLuxottica S.A. ESLOF | $92.4B | 53.83x | +21.1% | $5.04 |
 Fresenius SE & Co. KGaA FSNUY | $96.0B | 90.53x | +103.7% | $0.13 |
 Novartis AG NVSEF | $283.9B | 18.27x | -58.9% | $7.56 |
Industry Average 6 peers with valid PE | — | 44.43x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 14.11x | $23.00 | -48.3% | |
2024-12-31 FY2024 | 27.29x | $22.68 | -26.6% | |
2023-12-31 FY2023 | 37.17x | $18.62 | -3.9% | |
2022-12-31 FY2022 | 38.68x | $12.26 | +10.8% | |
2021-12-31 FY2021 | 34.91x | $10.40 | +44.3% | |
2020-12-31 FY2020 | 24.19x | $9.03 | +2.9% | |
2019-12-31 FY2019 | 23.50x | $8.20 | +27.2% | |
2018-12-31 FY2018 | 18.48x | $7.98 | -15.6% | |
2017-12-31 FY2017 | 21.89x | $7.70 | +29.8% | |
2016-12-31 FY2016 | 16.86x | $7.48 | -42.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novo Nordisk A/S (NONOF) measures how much investors pay for each dollar of the company's trailing earnings. NONOF's current PE ratio of 9.91x is calculated by dividing its stock price of $41.25 by its TTM earnings per share of $27.45.
Frequently asked questions
NONOF pe ratio · 6 questionsNONOF's current PE ratio is 9.91x as of 2026-06-08, based on a stock price of $41.25 and TTM EPS of $27.45. Data sourced from Financial Modeling Prep via NONOF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08